Effect of hepatitis c virus infection in patients with cancer: Addressing a neglected population

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 1, 2015, Pages 41-50

  Torres, Harrys A ^a   Mahale, Parag ^a,b   Blechacz, Boris ^a   Miller, Ethan ^a   Kaseb, Ahmed ^a   Herlong, H Franklin ^a   Fowler, Nathan ^a   Jiang, Ying ^a   Raad, Issam I ^a   Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS C ANTIBODY; INTERLEUKIN 28B; NITAZOXANIDE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVOR; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PORTAL HYPERTENSION; RETROSPECTIVE STUDY; RISK REDUCTION; SECOND CANCER; SKIN TOXICITY; SOLID TUMOR; TREATMENT RESPONSE; AGED; BIOPSY; CHRONIC HEPATITIS C; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; LIVER; LIVER NEOPLASMS; MIXED INFECTION; MORTALITY; NEOPLASMS; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; VIROLOGY;

AGED; ANTIVIRAL AGENTS; BIOPSY; COINFECTION; DISEASE PROGRESSION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84921507630     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0007     Document Type: Conference Paper

References (41)

1. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012;55(Suppl 1):S10-15.
2. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;61(RR-4):1-32.
3. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469-477.
4. Fujii Y, Kaku K, Tanaka M, et al. Hepatitis C virus infection in patients with leukemia. Am J Hematol 1994;46:278-282.
5. Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999;46:2925-2930.
6. Faggioli P, De Paschale M, Tocci A, et al. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma. Haematologica 1997;82:38-42.
7. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002;3:333-340.
8. Jensen DM. A new era of hepatitis C therapy begins. N Engl J Med 2011;364:1272-1274.
9. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
10. Kemmer N, Neff GW. Managing chronic hepatitis C in the difficult-to-treat patient. Liver Int 2007;27:1297-1310.
11. Huang CF, Huang JF, Chen WC, et al. The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study. Hepatol Int 2013;7:180-187.
12. Peffault de Latour R, Levy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004;103:1618-1624.
13. Peffault de Latour R, Asselah T, Levy V, et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 2005;36:709-713.
14. Ljungman P, Locasciulli A, de Soria VG, et al. Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy. Bone Marrow Transplant 2012;47:1217-1221.
15. Allison RD. Increased risk of extra-hepatic cancer mortality among persons with chronic hepatitis C infection. Presented at: Annual meeting of the American College of Preventive Medicine; February 19-22, 2014; New Orleans, Louisiana.
16. Locasciulli A, Alberti A. Hepatitis C virus serum markers and liver disease in children with leukemia. Leuk Lymphoma 1995;17:245-249.
17. Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012;9:156-166.
18. Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology 2009;50:387-392.
19. Mira JA, Rivero-Juarez A, Lopez-Cortes LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis 2013;56:1646-1653.
20. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-1238.
21. Ramos CA, Saliba RM, de Padua L, et al. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 2009;94:249-257.
22. Torres HA, Adachi JA, Roach LR, et al. Hepatitis C clinic operated by infectious disease specialists at a comprehensive cancer center: help is on the way. Clin Infect Dis 2012;54:740-742.
23. Davila JA, Morgan RO, Shaib Y, et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127:1372-1380.
24. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 2003;125:1723-1732.
25. Montella M, Crispo A, de Bellis G, et al. HCV and cancer: a case-control study in a high-endemic area. Liver 2001;21:335-341.
26. Antonelli A, Ferri C, Fallahi P, et al. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid 2007;17:447-451.
27. Donelli MG, Zucchetti M, Munzone E, et al. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998;34:33-46.
28. Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther 2013;37:1132-1156.
29. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
30. Matthews GV, Dore GJ. HIV and hepatitis C coinfection. J Gastroenterol Hepatol 2008;23(7 Pt 1):1000-1008.
31. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013;368:1907-1917.
32. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: http://hcvguidelines.org/. Accessed March 28, 2014.
33. Ascierto PA, Gogas HJ, Grob JJ, et al. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. Crit Rev Oncol Hematol 2013;85:149-161.
34. Talpaz M, Hehlmann R, Quintas-Cardama A, et al. Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia. Leukemia 2013;27:803-812.
35. van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 2008;11:77-98.
36. Mahale P, Kontoyiannis DP, Chemaly RF, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 2012;57:1177-1185.
37. Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-337.
38. Miyatake H, Kobayashi Y, Iwasaki Y, et al. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci 2012;57:1092-1101.
39. Breitenstein S, Dimitroulis D, Petrowsky H, et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009;96:975-981.
40. Safdar A. Difficulties with fungal infections in acute myelogenous leukemia patients: immune enhancement strategies. Oncologist 2007;12(Suppl 2):2-6.
41. Klingemann HG, Grigg AP, Wilkie-Boyd K, et al. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]. Blood 1991;78:3306-3311.